The U.S. Food and Drug Administration (FDA) has officially granted full approval to Moderna’s controversial mRNA COVID-19 vaccine, Spikevax, for children as young as 6 months old through 11 years of age who are deemed “at increased risk” of COVID-19. The vaccine was previously available to kids under Emergency Use Authorization (EUA), but the FDA has now handed over full approval, greenlighting the use of the experimental shot despite growing evidence of adverse events, including myocarditis, pericarditis, allergic reactions, and even seizures in young recipients. “COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We…

Click here to read the full article at The Gateway Pundit.

Login or subscribe today!

Login or Subscribe